Belantamab Monotherapy Demonstrates Safety and Durable Responses for Heavily Pretreated R/R MM: Results From DREAMM-20
Interim results from the phase 1 DREAMM-20 trial indicate that belantamab monotherapy is safe and clinically active in patients with relapsed/refractory (R/R) multiple myeloma (MM) who were previously exposed to multiple lines of prior of therapy.
These data were presented by Hang Quach, MD, St Vincent's Hospital, Melbourne, Australia, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Belantamab has previously demonstrated efficacy in R/R MM as part of the DREAMM-7 and DREAMM-8 trials. DREAMM-20 evaluates the naked antibody, GSK2857914, to assess its standalone clinical activity and safety. The primary end point was incidence of adverse events and dose-limiting toxicities. Secondary end points included overall response rate (ORR).
In this open-label dose-escalation study, 18 patients with ≥3 prior lines of therapy (94% triple-class exposed) were treated with belantamab monotherapy IV every 2 weeks at doses of 300 mg, 900 mg, or 2000 mg (n = 6 per cohort). The median age was 76 years (range, 42 to 86), and 2 patients had received prior BCMA-directed therapy.
The median duration of exposure was 63.5 days, and no dose-limiting toxicities or adverse reactions led to treatment discontinuation. The most common treatment-related adverse events were infusion reactions (22%) and hematologic events. The most common grade 3 or higher adverse events were neutrophil count decrease (22%) and anemia (17%).
The overall response rate (ORR) was 28%, including 2 very good partial responses and 3 partial responses. Disease was observed in another five patients (28%).
“Durable responses were observed across dose levels in this triple-class–exposed population,” the researchers concluded. “Results support the hypothesis that belantamab provides clinical anti-myeloma activity with an acceptable safety profile.”
Source:
Quach H, Augustson B, Barton L, et al. Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract 7550.
